



(51) International Patent Classification:

C12N 9/02 (2006.01) *C12Q 1/66* (2006.01)
A01K 67/027 (2006.01) *G01N 33/50* (2006.01)
C12N 15/85 (2006.01)

(21) International Application Number:

PCT/US2010/060909

(22) International Filing Date:

17 December 2010 (17.12.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/288,480	21 December 2009 (21.12.2009)	US
61/298,973	28 January 2010 (28.01.2010)	US
61/318,919	30 March 2010 (30.03.2010)	US
1057663	23 September 2010 (23.09.2010)	FR

(71) Applicant (for all designated States except US):
SANOFI-AVENTIS [FR/FR]; 174 avenue de France,
 F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DRESSLER, Holly** [US/US]; c/o sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **ECONOMIDES, Kyriakos D.** [US/US]; c/o sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **PANG, Zhen** [CN/US]; c/o sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **POLITES, Harry Gregory** [US/US]; c/o sanofi-aventis U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US).

(74) Agents: **SZCZEPANIK, Ann Marie** et al.; sanofi-aventis U.S. Inc., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,

[Continued on next page]

(54) Title: TRANSGENIC NON-HUMAN ANIMAL AND USES THEREOF




Figure 1

(57) Abstract: The present invention relates generally to transgene constructs, transgenic non-human animals comprising transgene constructs, methods of making and methods of using the transgenic non-human animals comprising transgene constructs. An embodiment of the invention relates to methods of assaying the activation of GPCR ligands non-invasively in whole animals, tissue slices, or in native cells using a transgenic model containing a bioluminescent transgene reporter system that is responsive to pathway modulation following ligand binding of GPCR receptors.



DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*